VTFN Stock Chart & Stats
€12.08
-€0.26(-1.42%)
At close: 4:00 PM EST
€12.08
-€0.26(-1.42%)
Day’s Range― - ―
52-Week Range€7.46 - €13.66
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€1.16B
Enterprise Value€12.66K
Total Cash (Recent Filing)€823.00M
Total Debt (Recent Filing)€1.60B
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Oct 22, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-36.80
Shares Outstanding135,447,190
10 Day Avg. Volume3
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio40.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)€310.32M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables FranchiseVitrolife's consumables are recurring, procedure-tied products. Record SEK 358m consumables and 15% organic Americas growth indicate durable, repeatable revenue less tied to capital cycles. That supports predictable topline and recurring cash flow over multiple quarters as clinics continue procedures.
Margin Expansion And Cost DisciplineSustained gross margin improvement and a materially higher EBITDA margin, combined with SEK 65m targeted restructuring savings and lower opex, increase operating leverage. If maintained, these structural improvements enhance profitability resilience and free up resources for strategic investment despite softer sales.
Positive Cash Generation And Conservative LeverageConsistent positive operating and free cash flow alongside low leverage provides financial flexibility. This durable cash generation reduces refinancing risk, supports shareholder returns and reinvestment, and helps the company manage cyclical headwinds without heavy dependence on external financing.
Bears Say
Sharp Revenue Decline And Deep LossesA ~41% TTM revenue contraction and very large net losses materially erode equity and produce deeply negative ROE. Persistent top-line decline and loss-making results impair reinvestment capacity, could constrain strategic initiatives, and threaten long-term financial flexibility if recovery stalls.
Structural China/APAC Demand WeaknessManagement flags ongoing demographic-driven weakness in China and APAC sales declines. As a major market, persistent lower IVF procedure volumes there reduce addressable demand and can materially slow multi-quarter revenue recovery across consumables and capital equipment.
Genetics Contraction And Strategic ExitsThe genetics business has contracted due to strategic exits and low-cost competition. While margin-focused, these exits reduce diversification and the high-growth diagnostics exposure long-term, limiting upside from reproductive genetics and narrowing future revenue streams.
Vitrolife AB News
VTFN FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was €7.46 and its highest was €13.66 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is €1.16B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Oct 22, 2026 which is in 56 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Jul 16, 2026. The company reported €0.087 earnings per share for the quarter, beating the consensus estimate of €0.082 by €0.006.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB does not currently pay dividends.
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.09.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of €0.087 in its last earnings report, beating expectations of €0.082. Following the earnings report the stock price went down -0.386%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in DE:VTFN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―